Inhibitor shows lasting structural integrity and long terminal half-life in tumor tissue

Omomyc is a first in class MYC inhibitor that targets the MYC oncogene which is deregulated in most tumor types. This therapeutic mini-protein was developed in-house by the Vall d'Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) spin-off company Peptomyc S.L. which was co-founded by VHIO's Laura Soucek in 2014, and continues to show clinical promise as the first direct inhibitor of MYC.

source https://medicalxpress.com/news/2023-02-inhibitor-terminal-half-life-tumor-tissue.html